Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Seattle Genetics, Inc.    SGEN

SEATTLE GENETICS, INC. (SGEN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/14/2018 06/15/2018 06/18/2018 06/19/2018 06/20/2018 Date
65.49(c) 65.11(c) 65.75(c) 65.78(c) 66.76 Last
1 283 021 2 040 569 744 772 818 963 664 286 Volume
-3.76% -0.58% +0.98% +0.05% +1.49% Change
More quotes
Financials (USD)
Sales 2018 601 M
EBIT 2018 -261 M
Net income 2018 -276 M
Finance 2018 526 M
Yield 2018 -
Sales 2019 783 M
EBIT 2019 -120 M
Net income 2019 -117 M
Finance 2019 554 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 16,4x
EV / Sales2019 12,6x
Capitalization 10 403 M
More Financials
Company
Seattle Genetics, Inc. engages in the development and commercialization of antibody-based therapies for the treatment of cancer.Its product ADCETRIS is an antibody-drug encompassing several settings for the treatment of relapsed Hodgkin lymphoma, for relapsed systemic anaplastic large cell... 
More about the company
Surperformance© ratings of Seattle Genetics, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on SEATTLE GENETICS, INC.
06/15SEATTLE GENETICS : Announces First Patient Dosed in Phase 2 Trial of Tisotumab V..
AQ
06/14SEATTLE GENETICS : and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Pa..
AQ
06/14ASTELLAS PHARMA : and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedoti..
AQ
06/14SEATTLE GENETICS : Announces First Patient Dosed in Phase 2 Trial of Tisotumab V..
AQ
06/13SEATTLE GENETICS : Announces First Patient Dosed in Phase 2 Trial of Tisotumab V..
BU
06/07SEATTLE GENETICS, INC. : Today's Free Research Reports Coverage on Seattle Genet..
AC
06/06SEATTLE GENETICS : to Present at the Goldman Sachs 39th Annual Global Healthcare..
BU
06/05ASTELLAS PHARMA : and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedoti..
AQ
06/04SEATTLE GENETICS : Highlights Additional Analyses from Phase 3 ECHELON-1 Clinica..
BU
06/03SEATTLE GENETICS : and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Pa..
BU
More news
Sector news : Biotechnology & Medical Research - NEC
02:59pGILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
08:02aLatecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
01:10pSeattle Genetics’ Hodgkin’s lymphoma drug gets U.S. approval  
02:03a$SGEN ALERT: New Seattle Genetics SEC Filing From our Stock News Alerts App 
06/19Seattle Genetics Sees Unusually Large Options Volume $SGEN  
06/19Didi Chuxing president Jean Liu's advice for working women: "It's supposed to..
4
06/18Seattle Genetics $SGEN Cut to Hold at ValuEngine  
More tweets
Qtime:89
News from SeekingAlpha
06/15YOUR DAILY PHARMA SCOOP : Wright Receives PMA, Allergan And Corbus Report Positi.. 
06/14Autolus Therapeutics Readies $125 Million U.S. IPO 
06/13Seattle Genetics commences mid-stage study of tisotumab vedotin in cervical c.. 
06/11Premarket analyst action - healthcare 
06/07CORE BIOTECH BUYS #18 : Thoughts On ASCO And The End Of Core Biotech 
Chart SEATTLE GENETICS, INC.
Duration : Period :
Seattle Genetics, Inc. Technical Analysis Chart | SGEN | US8125781026 | 4-Traders
Technical analysis trends SEATTLE GENETICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 68,5 $
Spread / Average Target 4,2%
EPS Revisions
Managers
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson CFO & Principal Accounting Officer
Vaughn B. Himes Chief Technical Officer
Roger D. Dansey Chief Medical Officer
Srinivas Akkaraju Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SEATTLE GENETICS, INC.22.90%10 403
CELLTRION, INC.--.--%34 574
IQVIA HOLDINGS INC8.22%21 638
LONZA GROUP1.10%20 183
INCYTE CORPORATION-23.96%15 266
ALNYLAM PHARMACEUTICALS, INC.-17.65%10 678